Acute hepatitis B with delta-agent infection
ICD-10 B16.1 is a billable code used to indicate a diagnosis of acute hepatitis b with delta-agent infection.
Acute hepatitis B with delta-agent infection is a viral infection of the liver caused by the hepatitis B virus (HBV) in conjunction with the hepatitis D virus (HDV), also known as the delta agent. This condition occurs when a person is simultaneously infected with both HBV and HDV, leading to a more severe form of hepatitis. The delta agent requires the presence of HBV to replicate, making co-infection particularly concerning. Symptoms may include jaundice, fatigue, abdominal pain, and elevated liver enzymes. Acute hepatitis B can progress to chronic infection, especially in individuals with compromised immune systems. The transmission routes primarily include percutaneous exposure to infected blood, sexual contact, and from mother to child during childbirth. Management of acute hepatitis B with delta-agent infection focuses on supportive care, monitoring liver function, and preventing complications such as liver failure or cirrhosis. Chronic management may involve antiviral therapy and regular surveillance for liver disease progression.
Detailed history of liver function tests, imaging studies, and treatment plans.
Patients presenting with jaundice, elevated liver enzymes, or acute liver failure.
Ensure documentation reflects the dual infection and any complications.
Comprehensive history of exposure, serological testing results, and treatment response.
Patients with recent travel history or high-risk behaviors presenting with hepatitis symptoms.
Document any co-morbid conditions that may affect treatment outcomes.
Used to confirm the presence of HBV in patients suspected of hepatitis.
Document the reason for testing and results.
Gastroenterology may require additional liver function tests.
Symptoms may include jaundice, fatigue, abdominal pain, nausea, and elevated liver enzymes. Some patients may be asymptomatic.
Diagnosis is made through serological testing for HBsAg and anti-HDV antibodies, along with clinical evaluation.
Treatment is primarily supportive, focusing on monitoring liver function and managing symptoms. Antiviral therapy may be considered in severe cases.
